Therapeutic effects of troglitazone in experimental chronic pancreatitis in mice

Area of Science:

• Biochemistry
• Cell Biology
• Gastroenterology

Background:

• Peroxisome proliferator-activated receptor (PPAR)-gamma plays a key role in regulating cellular processes, including inflammation.
• PPAR-gamma agonists have shown potential in inhibiting pancreatic stellate cell activation, a critical factor in fibrosis development.
• Chronic pancreatitis involves significant pancreatic damage and fibrosis, necessitating effective therapeutic strategies.

Purpose of the Study:

• To investigate the therapeutic effects of troglitazone, a PPAR-gamma ligand, on pancreatic damage and fibrosis in a mouse model of chronic pancreatitis.
• To evaluate whether troglitazone treatment is effective when initiated early or after the establishment of pancreatic damage.

Main Methods:

• Experimental chronic pancreatitis was induced in mice using cerulein injections over six weeks.
• Mice were treated with troglitazone either concurrently with cerulein (weeks 1-6) or after initial damage (weeks 4-6).
• Pancreatic damage, fibrosis, pancreatic stellate cell activation, and key molecular markers were assessed histopathologically and biochemically.

Main Results:

• Cerulein-induced chronic pancreatitis led to significant histopathological damage and fibrosis in mice.
• Troglitazone treatment significantly improved all assessed markers of pancreatitis severity.
• Both early and delayed troglitazone administration effectively reduced intrapancreatic fibrosis, pancreatic stellate cell numbers, and transforming growth factor-beta levels.

Conclusions:

• Troglitazone demonstrates significant anti-inflammatory and anti-fibrotic effects in experimental chronic pancreatitis.
• The therapeutic benefits of troglitazone are evident regardless of whether treatment is initiated early or used as a later intervention.
• PPAR-gamma activation represents a promising therapeutic target for managing chronic pancreatitis and its associated fibrosis.